Evidence map›Paper›PMID 39627816›Full record

Trial reportStem cell research & therapy2024

Co-infusion of mesenchymal stromal cells to prevent GVHD after allogeneic hematopoietic cell transplantation from HLA-mismatched unrelated donors after reduced-intensity conditioning: a double-blind randomized study and literature review.

Gérôme Lombardo, Chantal Lechanteur, Alexandra Briquet, Laurence Seidel, Evelyne Willems, Sophie Servais, Etienne Baudoux, Tessa Kerre, Pierre Zachee, Julie Herman and 4 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. [Research advances in mesenchymal stem cell therapy for graft-versus-host disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Simultaneous Co-transplantation for Highly Efficient Cell Therapy.Current stem cell research & therapy · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gérôme LombardoDepartment of Clinical Hematology, CHU of Liège, 1 Avenue de L'hôpital, 4000, Liège, Belgium.
Chantal LechanteurLaboratory of Cell and Gene Therapy, CHU and University of Liège, Liège, Belgium.
Alexandra BriquetLaboratory of Cell and Gene Therapy, CHU and University of Liège, Liège, Belgium.
Laurence SeidelCenter for Biostatistics and Research Methods, CHU and University of Liège, Liège, Belgium.
Evelyne WillemsDepartment of Clinical Hematology, CHU of Liège, 1 Avenue de L'hôpital, 4000, Liège, Belgium.
Sophie ServaisDepartment of Clinical Hematology, CHU of Liège, 1 Avenue de L'hôpital, 4000, Liège, Belgium.
Etienne BaudouxLaboratory of Cell and Gene Therapy, CHU and University of Liège, Liège, Belgium.
Tessa KerreDepartment of Clinical Hematology, Ghent University Hospital, Ghent, Belgium.
Pierre ZacheeDepartment of Clinical Hematology, ZNA Stuivenberg, Antwerp, Belgium.
Julie HermanDepartment of Clinical Hematology, CHU of Liège, 1 Avenue de L'hôpital, 4000, Liège, Belgium.
Audrey JanssenDepartment of Clinical Hematology, CHU of Liège, 1 Avenue de L'hôpital, 4000, Liège, Belgium.
Joséphine MullerDepartment of Clinical Hematology, CHU of Liège, 1 Avenue de L'hôpital, 4000, Liège, Belgium.
Frédéric BaronDepartment of Clinical Hematology, CHU of Liège, 1 Avenue de L'hôpital, 4000, Liège, Belgium.
Yves BeguinDepartment of Clinical Hematology, CHU of Liège, 1 Avenue de L'hôpital, 4000, Liège, Belgium. yves.beguin@uliege.be.ORCID 0000-0003-4650-7520

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMesenchymal stromal cells (MSC) have immunomodulatory and hematopoiesis-supporting properties that could potentially benefit hematopoietic stem cell (HSC) engraftment and decrease the incidence and/or severity of graft-versus-host disease (GVHD).

methodsBased on our previous pilot study, we established a multicenter, prospective, randomized, double-blind trial evaluating the efficacy of co-infusing third-party MSC (1.5-3 × 10

resultsThe study planned to include 120 patients to improve 1-year overall survival (OS) from 55 to 77% but was stopped after 9 years for low recruitment (n = 38). One-year OS was 74% in the MSC group and 80% in the placebo group. In multivariate analysis, the incidence of grade II-IV acute GVHD was significantly lower in patients receiving MSC (HR 0.332, 95% CI 0.124-0.890, p = 0.0284). No difference was observed in the incidences of chronic GVHD, infection or relapse, overall or progression-free survival at 1 year or long-term, or hematopoietic and immune reconstitution.

conclusionsDespite premature study closure, the suggested beneficial effect of MSC co-transplantation for the prevention of acute GVHD in HLA-mismatched HCT warrants further investigation.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationMesenchymal Stem CellsMesenchymal Stem Cell TransplantationTransplantation ConditioningAdolescentAdultAgedDouble-Blind MethodFemaleHLA AntigensHumansMaleMiddle AgedTransplantation, HomologousUnrelated DonorsHLA AntigensAllogeneic hematopoietic cell transplantationGVHDHLA mismatchMesenchymal stromal cellsPrevention

Identifiers

PMID39627816
PMCPMC11613890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.